Working… Menu
Trial record 87 of 2028 for:    doxil

A Study to Determine the Activity of Caelyx With Trastuzumab and Docetaxel in the Treatment of Metastatic Breast Cancer (Study P03679)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00687440
Recruitment Status : Completed
First Posted : May 30, 2008
Results First Posted : February 15, 2010
Last Update Posted : July 3, 2018
MDS Pharma Services
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.

Brief Summary:
The purpose of this study is to evaluate, in a first stage, the safety (incidence of cardiac toxicity) of Caelyx in combination with Trastuzumab and Docetaxel; and in a second stage, the tumor response rate of this regimen. This study will be conducted in approximately 30 centers. A total of approximately 70 to 95 subjects will be enrolled.

Condition or disease Intervention/treatment Phase
Breast Neoplasm Drug: Pegylated Liposomal Doxorubicin Drug: Docetaxel Drug: Trastuzumab Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 27 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Pegylated Liposomal Doxorubicin (Caelyx) in Combination With Herceptin and Taxotere as First-line Chemotherapy in Metastatic Breast Cancer Patients: A 2 Stage Phase II, Open Label, Multicenter Study.
Actual Study Start Date : July 15, 2005
Actual Primary Completion Date : October 24, 2008
Actual Study Completion Date : October 24, 2008

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer

Arm Intervention/treatment
Experimental: Caelyx, Docetaxel, Trastuzumab

Stage 1: subjects will receive Caelyx one day every 3 weeks in combination with docetaxel one day every 3 weeks and trastuzumab once weekly during 6 cycles. At the end of this stage, based on the number of cardiac events, subjects will proceed to a second stage or restart with a lower dose of Caelyx.

Stage 2: subjects will be treated with the recommended dose of Caelyx (defined in the first stage) in combination with docetaxel and trastuzumab.

Drug: Pegylated Liposomal Doxorubicin

Stage 1: 25 subjects will be treated with Caelyx IV 30 mg/m^2 on day 1, every 3 weeks

Stage 2: 45 new patients will be treated at the recommended dose level (defined in the first step) on day 1, every 3 weeks.

Other Name: Caelyx

Drug: Docetaxel
Stage 1 and Stage 2: Docetaxel 60 mg/m2 IV as 1-hour infusion, on day 1, every 3 weeks.
Other Name: Taxotere

Drug: Trastuzumab
Stage 1 and Stage 2: 4 mg/kg IV 90-minute infusion loading dose. Then 2 mg/kg IV weekly during 6 cycles (18 weeks).

Primary Outcome Measures :
  1. Number of Participants Who Had a Tumor Response, According to Standard RECIST (Response Evaluation Criteria in Solid Tumors) Criteria [ Time Frame: Week 09, Week 18, at the end of each patient's treatment, and at 3, 6, 9, and 12 months after end of treatment. ]
    Those who achieved either complete (disappearance of all target lesions) or partial (at least 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD) response.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

Patients must fulfill all the following criteria:

  • Females aged 18 to 70 years-old.
  • Willingness to participate in the study and comply with its procedures.
  • Documented diagnosis of metastatic breast carcinoma (stage IV) Human Epidermal Growth Factor Receptor 2 (HER2) overexpressing (Immunohistochemistry (IHC) 3+ or Fluorescence In Situ Hybridization(FISH) +).
  • No prior chemotherapy for metastatic breast cancer.
  • Adjuvant or neo-adjuvant chemotherapy is allowed according to the following rules:

    • patients treated with anthracyclines if all the following conditions are met:

      • Doxorubicin total dose <= 300 mg/m^2
      • Epirubicin total dose <= 480 mg/m^2
      • Chemotherapy-free interval of > 12 months
    • no taxane-based adjuvant or neo-adjuvant chemotherapy is allowed;
    • patients treated with non-anthracycline/taxane adjuvant or neo-adjuvant chemotherapy regimens are freely eligible (i.e. cyclophosphamide/methotrexate/fluorouracil (CMF) or similar regimens).
  • At least one measurable lesion according to RECIST criteria.
  • Complete hematologic and biologic baseline evaluation within 2 weeks prior to start of treatment.
  • Complete Tumor baseline evaluation including a total body computed tomography (CT) scan within 4 weeks prior to start of treatment.
  • Left ventricular ejection fraction (LVEF) >= 50% as determined by echocardiogram or Multi Gated Acquisition (MUGA) scan.
  • World Health Organization (WHO) performance status 0,1.
  • Life expectancy > 3 months.
  • Laboratory requirements :

    • Hematology :

      • Neutrophils > 1.5 x 10^9/L
      • Platelets > 100 x 10^9/L
      • Hemoglobin > 10 g/dL
    • Hepatic function:

      • Total bilirubin <= 1.25 x the upper-normal limits (UNL);
      • ASAT (Aspartate Aminotransferase or SGOT), ALAT (Alanine aminotransferase or SGPT) <= 2.5 x the upper-normal limits;
    • For patients with liver metastases:

      • Total bilirubin < 1.5 x the UNL (Upper limit of normal) ;
      • ASAT and/or ALAT < 3 x the UNL;
    • Renal function :

      • Serum Creatinine < 1.5 x the UNL.
  • Women of child bearing potential must have a negative serum pregnancy test and be using adequate contraception.
  • Patients must be accessible for treatment and follow-up.

Exclusion Criteria:

Patients will not be enrolled if any of the following criteria apply:

  • Prior chemotherapy for metastatic disease.
  • History of prior malignancy in the last 10 years (other than non melanoma skin cancer or excised cervical carcinoma in situ).
  • Radiation to disease areas within 3 weeks of study initiation.
  • Symptomatic peripheral neuropathy > grade 2 according to the National Cancer Institute (NCI) Common Toxicity Criteria.
  • Other serious illness or medical condition.
  • LVEF < 50% as determined by echocardiogram or MUGA scan.
  • Congestive hearth failure or angina pectoris even if it is medically controlled. Previous history of myocardial infarction within 1 year from study entry, uncontrolled high risk hypertension or arrhythmia.
  • History of significant neurologic or psychiatric disorders including dementia or seizures.
  • Active infection.
  • Active peptic ulcer, unstable diabetes mellitus or other contraindications for the use of dexamethasone.
  • Concurrent treatment with other experimental drugs. Participation in another clinical trial with any investigational drug within 30 days prior to study screening.
  • Concurrent treatment with corticosteroids used for reasons other than for premedication. However patients receiving chronic treatment with corticosteroids (> 6 months) at low dose (< 20 mg of methylprednisolone or equivalent dose of other corticosteroids) for whichever reason are eligible.
  • Taxane-based adjuvant or neo-adjuvant chemotherapy < 12 months.
  • Other concurrent chemotherapy, immunotherapy, radiotherapy or any other investigational medication, for the treatment of the tumor.
  • Pregnant or breast-feeding women.

Layout table for additonal information
Responsible Party: Merck Sharp & Dohme Corp. Identifier: NCT00687440     History of Changes
Other Study ID Numbers: P03679
Eudract No. 2004-003989-15
First Posted: May 30, 2008    Key Record Dates
Results First Posted: February 15, 2010
Last Update Posted: July 3, 2018
Last Verified: June 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description:

Additional relevant MeSH terms:
Layout table for MeSH terms
Liposomal doxorubicin
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Antibiotics, Antineoplastic
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Antineoplastic Agents, Immunological